Uncontrolled Polycythemia Vera: Case 1
Uncontrolled Polycythemia Vera
August 2014
- A 67-year-old female is diagnosed PV after complaining of fatigue
- Physical Exam was unremarkable
- CBC:
- HCT, 48%
- WBC, 12,100/μL
- Platelets, 603,000/μL
- Mutation testing: JAK2 V617F-positive
- The patient was started on treatment with low-dose aspirin and hydroxyurea 500 mg/day
- Her symptoms resolved within 3 months
February 2016
- She now complains of left upper quadrant pain
- For 1.5 years, the patient was maintained on treatment; however, for the past 9 months her hematocrit has risen to 48% and she has required 4 phlebotomies in last 6 months
- Hydroxyurea was increased from 500 mg to 1,000 mg daily
- Physical Exam: remarkable for splenomegaly
August 2016
- Physical Exam: still remarkable for splenomegaly, slightly smaller
- HCT 47.5%
Rossetti Reviews Myelofibrosis Risk Stratification and Outcome Data for Pacritinib
July 17th 2024During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and treatment for a patient with declining hemoglobin and platelet counts due to primary myelofibrosis.
Read More
Phase 3 VERIFY Trial Investigates Rusfertide’s Potential in Polycythemia Vera
July 16th 2024In an interview, Aniket Bankar, MD, discussed the background, design, and goals of the phase 3 VERIFY trial of the hepcidin mimetic rusfertide for the treatment of patients with polycythemia vera.
Read More
Ruxolitinib Treatment in Myelofibrosis Still Effective, Regardless of Anemia
June 21st 2024New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.
Read More
Challenging Disease Features of Myelofibrosis Lead to Use of JAK Inhibitors
June 17th 2024During a Case-Based Roundtable® event, Kristen Pettit, MD, moderated a discussion on which disease features of myelofibrosis are most challenging and when to use JAK inhibitors in the first article of a 2-part series.
Read More
